Methoxsalen Macopharma

Methoxsalen, the active ingredient in Methoxsalen Macopharma, is a psoralen presented as a pharmaceutical preparation for extracorporeal use. It is employed in photochemotherapy for conditions such as vitiligo and psoriasis, primarily in patients requiring controlled UVA exposure. GNH USA supplies Methoxsalen Macopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methoxsalen is used in photochemotherapy for disorders that respond to UVA‑activated agents. - Vitiligo: helps repigment depigmented skin areas when combined with UVA therapy. - Psoriasis: reduces plaque formation and scaling by inhibiting keratinocyte proliferation. - Other photodermatoses: may be employed under specialist supervision to control disease activity.

Methoxsalen can cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Skin erythema: redness at treated sites. - Pruritus: itching of the skin. - Phototoxicity: heightened skin sensitivity to UVA.

Serious or Rare Side Effects: - Severe phototoxic burns: extensive skin damage after UVA exposure. - Hemolysis in G6PD deficiency: rapid breakdown of red blood cells. - Liver enzyme elevation: potential hepatic stress. - Myelosuppression: reduced blood cell production. - Hypersensitivity reactions: rash, swelling, or anaphylaxis.

Methoxsalen requires careful handling and patient monitoring. - Dose adjustment: tailor based on patient response and UVA exposure. - Photoprotection: advise avoidance of sunlight outside treatment sessions. - Liver function: monitor hepatic enzymes periodically. - Blood counts: check complete blood count before and during therapy. - G6PD deficiency: screen patients to prevent hemolysis. - Store at ambient temperature: keep below 25°C, in original container, protected from moisture and light.

Methoxsalen may interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Antifungal azoles (e.g., ketoconazole): increase methoxsalen plasma levels. - Phenobarbital: may reduce therapeutic effect by inducing metabolism.

Moderate Interactions (Monitor Closely): - Oral contraceptives: potential reduction in efficacy. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Retinoids: may enhance cutaneous toxicity. - Immunosuppressants: assess combined immunomodulatory impact.